Last10K.com

Becton Dickinson Co (BDX) SEC Filing 10-K Annual Report for the fiscal year ending Thursday, September 30, 2021

Becton Dickinson Co

CIK: 10795 Ticker: BDX

Exhibit 99.1

1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com



bda18.jpg



Contact:
Investors: Nadia Goncalves, BD Investor Relations - 201-847-5934
Media: Troy Kirkpatrick, BD Public Relations - 858-617-2361



BD ANNOUNCES FOURTH FISCAL QUARTER AND FULL YEAR 2021 RESULTS; ISSUES FISCAL YEAR 2022 GUIDANCE

Fourth fiscal quarter revenues of $5.1 billion grew 7.3% on a reported basis or 5.9% on a currency-neutral basis.
Fiscal 2021 full-year revenues of $20.2 billion grew 18.3% on a reported basis or 15.6% on a currency-neutral basis.
Fourth fiscal quarter GAAP diluted earnings per share (EPS) increased 133.3% to $0.84; adjusted diluted EPS decreased 7.2% to $2.59.
Fiscal 2021 full-year GAAP diluted EPS increased 152.8% to $6.85; adjusted diluted EPS increased 28.2% to $13.08.
BD issues fiscal 2022 guidance of $19.3 to $19.5 billion in revenues and $12.30 to $12.50 adjusted diluted EPS; includes base business revenue growth of 5% to 6% on a currency-neutral basis with improved margin profile.
BD announced its 50th consecutive year of dividend increases; dividend raised 4.8%.

FRANKLIN LAKES, NJ (November 4, 2021)
- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for the fourth fiscal quarter and full fiscal year ended September 30, 2021.

“Our strong performance in fiscal 2021 was driven by the extraordinary efforts of our global team and demonstrates the resilience of BD’s portfolio in even the most uncertain health care environments,” said Tom Polen, chairman, CEO and president of BD. “We also took a number of critical steps this year to lay the foundation for the next phase of our growth, which included strengthening our balance sheet and cash flows, increasing our investments into higher-growth spaces, and stepping up our pace of tuck-in M&A activity. With increasing momentum in our base business and a clear path to accelerate margin recovery in fiscal 2022 and beyond, we are well-positioned to deliver on our commitments and drive long-term growth and value for all stakeholders.”




The following information was filed by Becton Dickinson Co (BDX) on Thursday, November 4, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Becton Dickinson Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Becton Dickinson Co.

Continue

Assess how Becton Dickinson Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Becton Dickinson Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
M & A
Legal
Other
Filter Subcategory:
All
Earnings
Expense
Cash Flow
Product
Income
Geography
Shares
Debt
Other
Inside Becton Dickinson Co's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Cover Page
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Income
Consolidated Statements Of Income
Accounting Changes
Benefit Plans
Benefit Plans (Tables)
Benefit Plans - Additional Information (Detail)
Benefit Plans - Change In Benefit Obligation, Change In Fair Value Of Plan Assets (Detail)
Benefit Plans - Expected Benefit Payments (Detail)
Benefit Plans - Fair Value Measurements Of Plan Assets (Detail)
Benefit Plans - Net Pension And Other Postretirement Cost (Detail)
Benefit Plans - Pension Plans With Accumulated Benefit Obligations (Detail)
Benefit Plans - Weighted Average Assumptions Determining Pension Plan (Detail)
Business Restructuring Charges
Business Restructuring Charges (Tables)
Business Restructuring Charges - Changes In Restructuring Balance (Detail)
Commitment And Contingencies (Policies)
Commitments And Contingencies
Commitments And Contingencies - Additional Information (Detail)
Debt
Debt (Tables)
Debt - Additional Information (Detail)
Debt - Extinguishments Of Debt (Details)
Debt - Schedule Of Debt Issuances (Details)
Debt - Summary Of Interest Costs And Payments (Detail)
Debt - Summary Of Long-Term Debt (Detail)
Debt - Summary Of Short-Term Debt (Detail)
Derivative Instruments And Hedging Activities
Derivative Instruments And Hedging Activities (Tables)
Derivative Instruments And Hedging Activities - Additional Information (Detail)
Derivative Instruments And Hedging Activities - Schedule Of Notional Amounts Of Outstanding Derivative Positions (Detail)
Derivative Instruments And Hedging Activities Disclosure - Gains (Losses) On Net Investment Hedges (Details)
Divestiture
Divestiture - Additional Information (Detail)
Earnings Per Share
Earnings Per Share (Tables)
Earnings Per Share - Weighted Average Common Shares Used In Computations Of Basic And Diluted Earnings Per Share (Details)
Earnings Per Share - Weighted Average Common Shares Used In Computations Of Basic And Diluted Earnings Per Share Footnotes (Details)
Financial Instruments And Fair Value Measurement - Cash And Equivalents And Restricted Cash (Details)
Financial Instruments And Fair Value Measurements
Financial Instruments And Fair Value Measurements (Tables)
Financial Instruments And Fair Value Measurements - Additional Information (Detail)
Financial Instruments And Fair Value Measurements - Schedule Of Fair Value, Assets And Liabilities Measured On Recurring Basis (Details)
Financial Instruments And Fair Value Measurements - Transfer Of Financial Assets Accounted For As Sales (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Components Of Income From Continuing Operations Before Income Taxes (Detail)
Income Taxes - Deferred Income Taxes (Detail)
Income Taxes - Provision For Income Taxes From Continuing Operations (Detail)
Income Taxes - Reconciliation Of Federal Statutory Tax Rate To Company's Effective Tax Rate (Detail)
Income Taxes - Summary Of Gross Amounts Of Unrecognized Tax Benefits (Detail)
Income Taxes - Summary Of Income Tax Holiday (Details)
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - Additional Information (Detail)
Intangible Assets - Components Of Intangible Assets (Detail)
Intangible Assets - Reconciliation Of Goodwill By Business Segment (Detail)
Leases - Lessee, Operating Lease, Liability, Maturity (Details)
Leases - Supplemental Balance Sheet Information Related To Leases (Details)
Leases, Codification Topic 842
Leases, Codification Topic 842 (Details)
Leases, Codification Topic 842 (Policies)
Leases, Codification Topic 842 (Tables)
Revenues
Revenues Revenues - Additional Information (Details)
Segment Data
Segment Data (Tables)
Segment Data - Additional Information (Detail)
Segment Data - Financial Information For Company's Segments (Detail)
Segment Data - Revenues To Unaffiliated Customers And Long-Lived Assets Including Property, Plant And Equipment (Detail)
Segment Data Segment Data - Revenues By Geographic Areas (Details)
Share-Based Compensation
Share-Based Compensation (Tables)
Share-Based Compensation - Additional Information (Detail)
Share-Based Compensation - Assumptions For Estimation Of Fair Values Of Stock Appreciation Rights Granted During Reporting Periods (Detail)
Share-Based Compensation - Compensation Cost Relating To Share-Based Payments (Detail)
Share-Based Compensation - Summary Of Performance-Based Restricted Stock Units Outstanding (Detail)
Share-Based Compensation - Summary Of Sars Outstanding (Detail)
Share-Based Compensation Fair Value Of Stock Units Vested (Details)
Share-Based Compensation Summary Of Sars Exercised (Details)
Share-Based Compensation Weighted Average Grant Date Fair Value Of Restricted Stock Units (Details)
Shareholders' Equity
Shareholders' Equity (Tables)
Shareholders' Equity - Accelerated Share Repurchases (Detail)
Shareholders' Equity - Accumulated Other Comprehensive (Loss) Income (Detail)
Shareholders' Equity - Additional Information (Detail)
Shareholders' Equity - Changes In Certain Components Of Shareholders' Equity (Detail Ii)
Shareholders' Equity - Changes In Certain Components Of Shareholders' Equity (Detail)
Shareholders' Equity - Other Comprehensive Income (Loss), Tax (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Supplemental Financial Information
Supplemental Financial Information (Tables)
Supplemental Financial Information - Inventories (Detail)
Supplemental Financial Information - Other Income (Expense), Net (Detail)
Supplemental Financial Information - Property, Plant And Equipment, Net (Detail)
Supplemental Financial Information - Trade Receivables, Allowances For Doubtful Accounts And Cash Discounts (Detail)
Ticker: BDX
CIK: 10795
Form Type: 10-K Annual Report
Accession Number: 0000010795-21-000091
Submitted to the SEC: Wed Nov 24 2021 2:57:19 PM EST
Accepted by the SEC: Wed Nov 24 2021
Period: Thursday, September 30, 2021
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/bdx/0000010795-21-000091.htm